Abstract
BackgroundBrain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults. The serum level of BDNF is altered in a diversity of neurological diseases. The aim of this work was to investigate the serum level of BDNF in patients with relapsing–remitting multiple sclerosis and the relation between BDNF and disease activity and severity.MethodsA case–control study was conducted on 90 subjects: 60 patients with relapsing–remitting multiple sclerosis (30 in relapse and 30 in remission) on different lines of medical treatment and 30 healthy volunteers as a control. Clinical, functional, and radiological evaluation was done for the patients, and all the patients and controls were subjected to assessment of the serum level of BDNF by sandwich-ELISA technique.ResultsThe BDNF level was significantly higher in MS patients in relapse than in patients in remission (P value = 0.006). In the remission group, there was no significant linear correlation between different MS patients’ characteristics and BDNF level, while in the relapse group, a positive linear correlation was found between the number of T2 infratentorial lesions and BDNF level (r = 0.402, P = 0.028). There was no statistically significant difference between the BDNF level in patients administered different drugs for MS in both remission and relapse groups (P value > 0.05).ConclusionBDNF was significantly higher in relapsing–remitting multiple sclerosis patients in the relapse phase. Attention should be paid to the link between serum BDNF level as a neuroprotective factor and multiple sclerosis; it can be a biomarker for MS activity in the near future.
Highlights
Multiple sclerosis is one of the most common neurological disorders in young adults
This study is a case–control study conducted on 90 subjects: sixty patients with relapsing–remitting multiple sclerosis diagnosed according to the International Panel on Diagnosis of Multiple Sclerosis “McDonald’s criteria 2017” [10] (30 in relapse and 30 in remission) on different lines of medical management
We studied the effect of Multiple sclerosis (MS) therapy on Brain-derived neurotrophic factor (BDNF) level
Summary
Multiple sclerosis is one of the most common neurological disorders in young adults. It is a chronic disease which is manifested by inflammation, demyelination, and axonal loss and most probably leads to a significant degree of disability [1].The chronic inflammation in multiple sclerosis pathology contradicts immune mechanisms that modulate and confine the inflammatory cascade to limit irreversible demyelination and axonal damage [2].Brain-derived neurotrophic factor (BDNF) was cloned in 1989 [3]. Multiple sclerosis is one of the most common neurological disorders in young adults It is a chronic disease which is manifested by inflammation, demyelination, and axonal loss and most probably leads to a significant degree of disability [1]. The chronic inflammation in multiple sclerosis pathology contradicts immune mechanisms that modulate and confine the inflammatory cascade to limit irreversible demyelination and axonal damage [2]. BDNF is the second recognized member in the neurotrophin family It is an activity-dependent secreted protein which is expressed widely in the central nervous system and implicated in the differentiation, survival, and growth of neurons. Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults. The aim of this work was to investigate the serum level of BDNF in patients with relapsing–remitting multiple sclerosis and the relation between BDNF and disease activity and severity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
